Pfizer returns pagoclone to Indevus
Executive Summary
Aventis will have 90 days from Pfizer's termination of pagoclone development contract with Indevus to decide whether to take over development of the anxiolytic, Indevus says. Indevus licensed the compound from Aventis (then Rhone Poulenc-Rorer) in 1994. Pfizer told Indevus June 6 that it will not pursue the drug for generalized anxiety disorder and panic disorder after trials failed to show statistical significance over placebo...